These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31732149)

  • 21. Pharmacokinetics of ciclesonide and desisobutyryl ciclesonide after administration via aqueous nasal spray or hydrofluoroalkane nasal aerosol compared with orally inhaled ciclesonide: an open-label, single-dose, three-period crossover study in healthy volunteers.
    Nave R; Herzog R; Laurent A; Wingertzahn MA
    Clin Ther; 2009 Dec; 31(12):2988-99. PubMed ID: 20110036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of fluticasone propionate multidose, inhalation-driven, novel, dry powder inhaler versus a prevailing dry powder inhaler and a metered-dose inhaler.
    Gillespie M; Song S; Steinfeld J
    Allergy Asthma Proc; 2015; 36(5):365-71. PubMed ID: 26314817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?
    Hochhaus G; Chen MJ; Kurumaddali A; Schilling U; Jiao Y; Drescher SK; Amini E; Berger SM; Kandala B; Tabulov C; Shao J; Seay B; Abu-Hasan MN; Baumstein SM; Winner L; Shur J; Price R; Hindle M; Wei X; Carrasco C; Sandell D; Oguntimein O; Kinjo M; Delvadia R; Saluja B; Lee SL; Conti DS; Bulitta JB
    AAPS J; 2021 Mar; 23(3):48. PubMed ID: 33768368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
    Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
    Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate.
    Fowler SJ; Orr LC; Wilson AM; Sims EJ; Lipworth BJ
    Br J Clin Pharmacol; 2001 Jul; 52(1):93-5. PubMed ID: 11453895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis.
    Davis GA; Rudy AC; Archer SM; Wermeling DP; McNamara PJ
    Pharmacotherapy; 2004 Jan; 24(1):26-32. PubMed ID: 14740785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder.
    Obaidi M; Offman E; Messina J; Carothers J; Djupesland PG; Mahmoud RA
    Headache; 2013 Sep; 53(8):1323-33. PubMed ID: 23992438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic Comparison of a Unit Dose Dry Powder Inhaler with a Multidose Dry Powder Inhaler for Delivery of Fluticasone Furoate.
    Mehta R; Moore A; Riddell K; Joshi S; Chan R
    J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):332-338. PubMed ID: 28463040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioavailability of inhaled fluticasone propionate via chambers/masks in young children.
    Blake K; Mehta R; Spencer T; Kunka RL; Hendeles L
    Eur Respir J; 2012 Jan; 39(1):97-103. PubMed ID: 21933835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies.
    Haughie S; Allan R; Wood N; Ward J
    J Aerosol Med Pulm Drug Deliv; 2020 Feb; 33(1):34-42. PubMed ID: 31364911
    [No Abstract]   [Full Text] [Related]  

  • 32. The efficacy of fluticasone propionate aqueous nasal spray for allergic rhinitis and its relationship to topical effects.
    Howland WC; Hampel FC; Martin BG; Ratner PH; van Bavel JH; Field EA
    Clin Ther; 1996; 18(6):1106-17. PubMed ID: 9001827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of intranasal mometasone in the fixed-dose combination GSP301 versus two monotherapy intranasal mometasone formulations.
    Patel P; Salapatek AM; Talluri RS; Tantry SK
    Allergy Asthma Proc; 2018 May; 39(3):232-239. PubMed ID: 29669668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
    Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
    Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NAVIGATE II: Randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis.
    Leopold DA; Elkayam D; Messina JC; Kosik-Gonzalez C; Djupesland PG; Mahmoud RA
    J Allergy Clin Immunol; 2019 Jan; 143(1):126-134.e5. PubMed ID: 29928924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two multicenter, randomized, single-blind, single-dose, crossover studies of specific sensory attributes of budesonide aqueous nasal spray and fluticasone propionate nasal spray.
    Shah SR; Miller C; Pethick N; Uryniak T; Jones MK; O'Dowd L
    Clin Ther; 2003 Aug; 25(8):2198-214. PubMed ID: 14512128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantification of fluticasone propionate in human plasma by LC-MS/MS and its application in the pharmacokinetic study of nasal spray at clinical doses.
    Yamagata A; Adachi R; Yokokawa A; Furihata T; Shibasaki H
    Drug Metab Pharmacokinet; 2024 Feb; 54():100541. PubMed ID: 38150944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease.
    Singh SD; Whale C; Houghton N; Daley-Yates P; Kirby SM; Woodcock AA
    Br J Clin Pharmacol; 2003 Apr; 55(4):375-81. PubMed ID: 12680886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deposition characteristics of a novel intranasal formulation of azelastine hydrochloride plus fluticasone propionate in an anatomic model of the human nasal cavity.
    Meltzer EO; Bachert C; Mayer MJ; Kopietz F; Koltun A; Maus J; D'Addio AD
    Allergy Asthma Proc; 2020 Jul; 41(4):265-270. PubMed ID: 32393418
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparison of once daily fluticasone propionate aqueous nasal spray with once daily budesonide reservoir powder device in patients with perennial rhinitis.
    Kivisaari E; Baker RC; Price MJ
    Clin Exp Allergy; 2001 Jun; 31(6):855-63. PubMed ID: 11422149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.